It was a pleasure to speak with Dr Sara Anvari (Baylor College of Medicine, Texas Children’s Hospital, TX, USA) about her presentation on the COVID-19 Vaccine Allergy Case Registry, where potential cases of severe hypersensitivity reactions to COVID-19 vaccines were collected.
The abstract entitled ‘Urticaria and/or angioedema events secondary to mRNA COVID-19 vaccinations -Updates from a national case registry’ (Abstract #L05) was presented at The American Academy of Allergy, Asthma & Immunology (AAAAI), February 25-28, 2022
- Could you tell us a little about the COVID-19 Vaccine Allergy Case Registry and its aims? (00:22)
- What were the findings of the registry study in terms of incidence of urticaria and/or angioedema events following mRNA vaccines for COVID-19? (01:28)
- How severe were these events and how were they treated? (02:16)
- What was the conclusion of the investigators regarding the suitability of future vaccine doses in patients who experienced these events? (04:00)
- What questions remain unanswered and what future studies are planned? (05:25)
Disclosures: Sara Anvari reports grants from NIH/NIAID (R01 AI135197 and UM2 AI130836) and DBV Technologies, outside the submitted work.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Shanice Allen.
Filmed in coverage of the virtual AAAAI 2022.
Share this Video
Related Videos In Dermatological Diseases
Victoria P. Werth, ACR 2022: The phase 3 DeterMine trial of lenabasum in dermatomyositis
DeterMine (NCT03813160) was a phase 3 randomized, double-blind, placebo-controlled study investigating the efficacy and safety of lenabasum for the treatment of dermatomyositis. It was a pleasure to talk with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) to discuss the aims, design, eligibility criteria and findings of the phase 3 study. This information […]
Loretta Fiorillo, EADV 2022: Findings from the Phase 3 Study of Apremilast in Paediatric Plaque Psoriasis
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. touchIMMUNOLOGY were delighted to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) to discuss the the aims, design and eligibility criteria of the study investigating apremilast in paediatric patients with moderate to severe plaque psoriasis and how […]
Loretta Fiorillo, EADV 2022: Apremilast Treatment for Plaque Psoriasis in Paediatric Patients
Apremilast is an oral small-molecule inhibitor of PDE4 currently approved in adult patients with plaque psoriasis. It was a pleasure to talk with Dr. Loretta Fiorillo (University of Alberta, Edmonton, Canada) around the unmet needs in the treatment of plaque psoriasis in paediatric patients and the clinical evidence supporting apremilast in this indication. The abstract […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!